Genscript Biotech (HK:1548) has released an update.
Genscript Biotech Corporation’s subsidiary, Legend Biotech, has announced promising results from a Phase 2 study on CARVYKTI® in treating multiple myeloma at the ASCO Annual Meeting and will present at the EHA Congress. The study shows that patients who had not achieved a complete response after an initial stem cell transplant could achieve deep and durable responses with a single infusion of the drug, with or without maintenance therapy. Shareholders are advised to consider investment risks and exercise caution when dealing with the company’s securities.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
